Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Intravenous antibiotic therapy effective against shunt infection in children

24 Jul 2020

Use of intravenous antibiotics is sufficient to treat children with ventriculoperitoneal (VP) shunt infections, particularly those infected by Gram-negative organisms and with cerebrospinal fluid (CSF) glucose level of >40 mg/dl, suggests an Iran study.

A total of 148 children (mean age, 21.2 months) were included in the analysis, of whom 56.1 percent were boys and 68.2 percent had responded to the protocol. Patients infected with Gram-negative bacteria (82.9 percent), specifically Acinetobacter spp. and Pseudomonas aeruginosa, showed the most significant response.

Of note, those with CSF glucose >40 mg/dl had significantly higher response to treatment (83 percent vs 58.1 percent; p=0.004).

This retrospective study included children <15 years of age with VP shunt infection, who had undergone treatment from March 2011 to March 2018 in the main referral hospital in Isfahan, Iran. Patients with distal shunt infection or associated wound infection were excluded.

The initial protocol consisted of empiric intravenous antibiotic therapy and repeated evaluation of CSF analysis and culture. Adjustments to antibiotic regimen according to sensitivity results were carried out after obtaining the culture results.

Response to protocol was defined as negative culture results after 72 hours of appropriate antibiotic, which persisted at least for 1 month after discontinuation of therapy. Shunts were replaced in patients who did not respond to the protocol.

“Infection is one of the most common complications of VP shunts,” the authors said, noting that its optimal management remains controversial.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.